ASPG and acute lymphoblastic leukemia: Most contemporary ALL protocols have replaced native E. coli-asparaginase with the long-acting formula, PEG-asparaginase, which may have a different thrombogenic profile, but few studies have addressed the effect of this change on the risk of thrombosis.